Laboratory of Experimental Surgery (IREC/CHEX), Université catholique de Louvain, Faculté de Médecine, Brussels, Belgium.
Biomaterials. 2011 Dec;32(34):8880-91. doi: 10.1016/j.biomaterials.2011.08.009. Epub 2011 Aug 27.
Adipose tissue was only recently considered as a potential source of mesenchymal stem cells (MSCs) for bone tissue engineering. To improve the osteogenicity of acellular bone allografts, adipose MSCs (AMSCs) and bone marrow MSCs (BM-MSCs) at nondifferentiated and osteogenic-differentiated stages were investigated in vitro and in vivo. In vitro experiments demonstrated a superiority of AMSCs for proliferation (6.1±2.3 days vs. 9.0±1.9 days between each passage for BM-MSCs, respectively, P<0.001). A significantly higher T-cell depletion (revealed by mixed lymphocyte reaction, [MLR]) was found for AMSCs (vs. BM-MSCs) at both non- and differentiated stages. Although nondifferentiated AMSCs secreted a higher amount of vascular endothelial growth factor [VEGF] in vitro (between 24 and 72 h of incubation at 0.1-21% O(2)) than BM-MSCs (P<0.001), the osteogenic differentiation induced a significantly higher VEGF release by BM-MSCs at each condition (P<0.001). After implantation in the paraspinal muscles of nude rats, a significantly higher angiogenesis (histomorphometry for vessel development (P<0.005) and VEGF expression (P<0.001)) and osteogenesis (as revealed by osteocalcin expression (P<0.001) and micro-CT imagery for newly formed bone tissue (P<0.05)) were found for osteogenic-differentiated AMSCs in comparison to BM-MSCs after 30 days of implantation. Osteogenic-differentiated AMSCs are the best candidate to improve the angio-/osteogenicity of decellularized bone allografts.
脂肪组织最近才被认为是用于骨组织工程的间充质干细胞（MSCs）的潜在来源。为了提高脱细胞骨同种异体移植物的成骨性，研究了未分化和成骨分化阶段的脂肪间充质干细胞（AMSCs）和骨髓间充质干细胞（BM-MSCs）的体外和体内情况。体外实验表明，AMSCs 在增殖方面具有优势（分别为每个传代的 6.1±2.3 天和 9.0±1.9 天，P<0.001）。在非分化和分化阶段，均发现 T 细胞耗竭（通过混合淋巴细胞反应[MLR]揭示）明显更高的 AMSCs（与 BM-MSCs 相比）。虽然未分化的 AMSCs 在体外（在 0.1-21%O2 下孵育 24 至 72 小时）分泌更高量的血管内皮生长因子[VEGF]（与 BM-MSCs 相比，P<0.001），但成骨分化在每种条件下都能显著提高 BM-MSCs 释放的 VEGF（P<0.001）。植入裸鼠的椎旁肌肉后，在血管生成（血管发育的组织形态计量学（P<0.005）和 VEGF 表达（P<0.001））和成骨（骨钙素表达（P<0.001）和新形成骨组织的微 CT 成像（P<0.05））方面，与 BM-MSCs 相比，成骨分化的 AMSCs 植入 30 天后均发现有明显改善。成骨分化的 AMSCs 是改善脱细胞骨同种异体移植物的血管生成/成骨性的最佳候选物。
